Research Of Serum Level And Clinical Significance Of Cartilage Oligomeric Matrix Protein In Spondyloarthropathies

BacgroundSeronegative spondyloarthropathy (Spondyloarthropathies, SpA) disease is also known as spondyloarthropathies. SpA is a group of interrelated multi-system inflammatory diseases, which violates the spine, peripheral joints and periarticular structures. It includes ankylosing spondylitis, reactive arthritis, psoriatic arthritis, Juvenile idiopathic arthritis, inflammatory bowel disease and arthritis, etc [1]. It can make irreversible bone destruction of sacroiliac joints, spine and peripheral joints, which occurs mainly in young men and causes signify-cant social and economic burden.Therefore early diagnosis and prompt effective treatment are very important. The cause of this disease is unknown. So far there are no recognized drugs to improve the condition. Therefore, the judgment of disease activity and clinical evaluation have very important significance for understanding the progress of the disease and evaluating the effectiveness of treatment. At present, the disease activity and outcome assessment in SpA are very limited. Clinical indicators such as BASDAI score are subject-tive, while the sensitivity and specificity of the erythrocyte sedimentation rate, C reactive protein and other inflammatory markers are very low. More sensitive and effective indica-tors of disease activity and efficacy evaluation are worth exploring. Cartilage oligomeric matrix protein (cartilage oligomeric matrix protein, COMP) is newly discovered cartilage metabolism marker in nearly10years [2]. It is a more sensitive serum marker, which can react the activities of synovitis and bone and cartilage destruction.There is more research at home and abroad in osteoarthritis and rheumatoid arthritis, but little research in spondylo-arthropathies.ObjectiveTo explore the serum level of cartilage oligomeric matrix protein (COMP) in relation to the disease activity and bone destruction.MethodsThe serum levels of COMP were measured by ELIS A of38patients with SpA and18 controls, and also10cases of patients with SpA before and after treatment with Etanercept The score of BSADAI, BSAFI, BASMI, ASDAS-ESR, ASDAS-CRP and the Night spinal pain (VAS) were recorded and the serum levels of erythrocyte sedimentation rate(ESR), C-reactive protein (CRP), tumor necrosis factor-alpha and Sacroiliac joints CT classification were examined at the same time. And their correlation with COMP were analyzed.ResultSignificantly increased serum level of COMP was found in SpA patients (30.835±8.539ng/ml) as compared to that in healthy controls (12.639±2.939ng/ml), two groups was statis-tically significant differences(P<0.01). The serum level of COMP was higher in24active patients (34.168±7.988ng/ml)than that in14inactive patients (25.122±6.243ng/ml), two groups was statistically significant differences (P=0.01). The serum level of COMP of ten cases after treatment(17.670±7.199ng/ml) with Etanercept obviously decreased before treatment (35.645±7.381ng/ml). COMP level was positively correlated with ESR,CRP, BSADAI,BSAFI, ASDAS-ESR,ASDAS-CRP and the Night spinal pain (VAS) and the sacroiliac joint CT grade (P<0.05),and has no significant correlation with age, duration, BASMI, Platelet,TNF-a and Peripheral joint injury (P>0.05).ConclusionsHigh serum levels of COMP indicated high disease activity and may indicate severe bone destruction. Serum level of COMP can be used for evaluating the disease activity and therapeutic effect of SpA.